Prestige Consumer Healthcare reported total revenues of $336.3 million for the quarter ended September 30, 2026, up from $274.1 million in the prior year, though net income decreased to $25.3 million due to higher interest expenses and acquisition-related costs. The company significantly expanded its balance sheet through a $1.19 billion acquisition, funded by new term loans and senior notes.
Prestige Consumer Healthcare reported Q2 fiscal 2027 revenue of $336.3 million, a 22.7% increase driven by the acquisitions of Breathe Right and LaCorium. Adjusted diluted EPS rose to $1.13 from $1.07 in the prior year, supported by strong consumption across eCommerce channels. The company adjusted its full-year revenue guidance to a range of $1.28 billion to $1.29 billion.
Term
Q2 2027
“We were pleased with our second quarter and first half revenue and EPS performance, driven by continued strength in our leading brands and strong early contributions from the Breathe Right® portfolio and LaCorium acquisitions that closed in June and July, respectively. Our portfolio performed in line with our expectations, with strong consumption growth across channels including eCommerce. This translated into strong mid-single-digit earnings growth and sets us up for continued strong free cash flow moving forward.”
Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare